Opthea Ltd (OPT) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
OPT currently has 1.23B outstanding shares. with limited dilution risk as only 11.5M additional shares (0.9%) are authorized for issuance. The company has diluted shareholders by 12.86% over the past 2 years through share issuances.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Sep 15, 2025 |
20-F filing | 1231.8M shares outstanding |
1.2B | 12M |
| Aug 30, 2024 |
20-F filing | 1091.5M shares outstanding |
1.1B | 12M |
| Sep 28, 2023 |
20-F filing | 467.2M shares outstanding |
470M | 12M |
| Sep 29, 2022 |
20-F filing | 352.2M shares outstanding |
350M | 12M |
| Feb 01, 2022 |
F-3 filing: This is an at the market offering of ADSs representing ordinary shares with an aggregate offering price of up to US$75,000,000 through Jefferies LLC. |
350M | 12M |
| Oct 28, 2021 |
20-F filing | 351.0M shares outstanding |
350M | 0 |
| Sep 24, 2020 |
F-1 filing: This F-1 filing describes the initial public offering of American Depositary Shares (ADSs) representing ordinary shares of Opthea Pty Ltd. The company intends to use the net proceeds to advance the clinical development of OPT-302 for the treatment of wet AMD, to advance non-clinical studies for the co-formulation of OPT-302 with an approved anti-VEGF-A therapy, and to fund other research and development activities. |
270M | 0 |